Clinical assessments of PD-L1, such as combined positive score (CPS) or tumor proportion score (TPS), have been used to identify patients eligible for ICI treatments or to predict their likelihood of response to ICI treatments (56, 57). This evidence concerns the gene CD274 and neoplasm.